Beam Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
BEAM-302 demonstrated robust efficacy and safety in 29 AATD patients, achieving durable, protective AAT levels and significant reduction of mutant Z-AAT with a single 60 mg dose. The therapy restored physiologic AAT regulation and showed a favorable safety profile, supporting advancement to pivotal trials.
-
Base editing technology is enabling one-time, durable therapies for genetic diseases, with BEAM-302 and Risto-cel advancing toward regulatory milestones and commercialization. Financial strength and platform scalability support rapid pipeline expansion and strategic partnerships.
Fiscal Year 2025
-
Expanded liver-targeted pipeline with BEAM-304 for PKU and secured $500M in non-dilutive financing to support risto-cel commercialization and pipeline growth. Strong cash position extends runway into mid-2029, with key clinical milestones ahead.
-
Base editing platform advances enable precise gene correction with strong safety and efficacy signals. AATD 302 program targets accelerated approval with robust biomarker data, while the sickle cell program shows rapid engraftment and high efficacy. Cash runway extends into 2028.
-
Base editing technology enables precise, repeatable gene correction, with BEAM-101 showing strong clinical results in sickle cell disease and BEAM-302 advancing for alpha-1 antitrypsin deficiency. Cost efficiencies and pipeline expansion are expected, with key data updates in 2025.
-
The discussion highlighted progress in gene editing for hematology and liver diseases, with BEAM-302 showing strong efficacy and safety in AATD. Early 2026 data will inform optimal dosing and regulatory path, while the sickle cell program advances toward pivotal results and potential approval.
-
The company is advancing base editing therapies for hematology and liver diseases, with BEAM-302 showing strong efficacy and safety in AATD and a one-time, durable correction profile. Competitive advantages include higher functional protein levels and a favorable safety profile, with regulatory and commercial milestones expected in early 2026.
-
Updated BEACON trial data show BEAM-101 achieves robust, durable increases in hemoglobin F and resolves anemia in severe sickle cell disease, with no severe VOCs post-engraftment and a favorable safety profile. Manufacturing is efficient and scalable, and market demand is strong.
-
Multiple base editing programs are advancing rapidly, with strong clinical data and a robust safety profile. Regulatory engagement is ongoing, with RMAT designation supporting accelerated approval discussions. Next-generation therapies and expanded indications are in development.
-
First clinical data for BEAM-302 in AATD showed strong safety, dose-dependent efficacy, and significant reduction of toxic protein, with potential for higher dosing. Proprietary LNP delivery is validated, supporting expansion into new liver programs. BEAM-101 in sickle cell disease continues to show best-in-class results.
-
Early data show a single-dose therapy can achieve and surpass the therapeutic threshold for AATD, offering a potential functional cure and halting disease progression. The approach promises significant patient convenience, cost savings, and a strong case for accelerated approval.
-
Initial phase I/II data for BEAM-302 in AATD show dose-dependent, durable increases in functional AAT above therapeutic thresholds, with significant reduction in toxic Z-AAT and a favorable safety profile. All patients at the highest dose exceeded target AAT levels, supporting further dose escalation and expansion.
-
The conference highlighted a clinically validated base editing platform enabling scalable, precise genetic therapies. Lead programs in sickle cell disease and alpha-1 antitrypsin deficiency are advancing rapidly, with key data and regulatory milestones expected this year.
-
Base editing technology is advancing with multiple clinical programs, including BEAM-101 for sickle cell and BEAM-302 for Alpha-1 antitrypsin deficiency, both leveraging a shared LNP platform. The company is focused on rapid clinical progress, regulatory flexibility, and targeting high unmet needs.
-
Base editing platform shows strong clinical progress in sickle cell and liver diseases, with BEAM-101 and BEAM-302 advancing toward key milestones. Manufacturing capacity and rapid engraftment are expected to drive market growth, while new delivery technologies and collaborations expand future potential.
Fiscal Year 2024
-
Base editing therapies show strong clinical progress in sickle cell disease, with BEAM-101 delivering rapid engraftment, robust fetal hemoglobin induction, and improved red blood cell function. ESCAPE's antibody-based conditioning expands patient reach, and BEAM-302 data is now expected in early 2025.
-
Base editing technology shows strong efficacy and safety in sickle cell disease, with BEAM-101 outperforming competitors in key clinical metrics. Next-generation products aim to expand patient eligibility and improve safety, while in vivo programs target curative therapies for genetic diseases.
-
Initial clinical data for Beam 101 in sickle cell disease show strong efficacy and safety, with rapid trial enrollment and deep hemoglobin correction. ESCAPE technology demonstrated robust preclinical results, potentially expanding patient access and improving safety.
-
Enrollment is progressing in a pivotal sickle cell trial, with clinical data expected later this year. The AAT in vivo gene editing program is set to dose its first patient in the UK this month, with initial data anticipated in 2025. Transient LFT elevations are not expected to be dose-limiting.